Name (Synonyms) | Correlation | |
---|---|---|
drug197 | Blood collection Wiki | 1.00 |
drug329 | Clinical interview Wiki | 1.00 |
drug1213 | Saliva collection Wiki | 0.71 |
drug1016 | Placebo Wiki | 0.08 |
Name (Synonyms) | Correlation | |
---|---|---|
D014947 | Wounds and Injuries NIH | 0.29 |
D055370 | Lung Injury NIH | 0.23 |
D055371 | Acute Lung Injury NIH | 0.12 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.10 |
D011014 | Pneumonia NIH | 0.07 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The study is a prospective, randomized, placebo-controlled, single-blind phase 2 clinical study of the efficacy and safety of CERC-002, a potent inhibitor of LIGHT, for the treatment of patients with COVID-19 pneumonia who have mild to moderate ARDS. LIGHT is a cytokine in the TNF super family (TNFSF14) which drives inflammation and induces many other cytokines including IL-1, IL-6 and GM-CSF. LIGHT levels have been shown to be elevated in COVID-19 infected patients and inhibiting LIGHT is hypothesized to ameliorate the cytokine storm which has shown to be a major factor in progression of ARDS. The study will assess the efficacy and safety of CERC-002 in patients with severe COVID-19 over a 28 day period as single dose on top of standard of care.
Description: Respiratory failure defined based on resource utilization requiring at least one of the following: Endotracheal intubation and mechanical ventilation Oxygen delivered by high-flow nasal cannula (heated, humidified oxygen delivered via reinforced nasal cannula at flow rates >20L/min with fraction of delivered oxygen ≥0.5) Noninvasive positive pressure ventilation, Extracorporeal membrane oxygenation
Measure: Proportion of patient alive and free of respiratory failure Time: Baseline to Day 28Description: 1-month mortality
Measure: Proportion of subjects who are alive Time: Baseline to Day 28